Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026Human reviewedUpdated Aug 2026

Evidence / Cardiometabolic Risk

CoverageCardiometabolic Risk

Can hormone therapy help insulin resistance in peri- and postmenopausal women?

Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026

Updated Aug 2026·14 studies analyzed·2 core studies·Applies to: postmenopausal women

Bottom line

Some studies show improved insulin sensitivity with estrogen-based therapy in early postmenopause, but results are not uniform across regimens. HRT should not replace evidence-based diabetes prevention or treatment.[1–6]

Evidence confidence

Evidence Confidence

Moderate
LimitedModerateHigh

Relevant evidence exists, but study designs, populations, or conclusions differ enough to keep certainty moderate.

Key uncertainty. Metabolic effects differ by estrogen type, route, and menopause stage; trials are heterogeneous and not powered for hard outcomes.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Ask this questionStart free trialWhy physicians use RAGMD

Also asked

HRT insulin resistance▼

Some studies show improved insulin sensitivity with estrogen-based therapy in early postmenopause, but results are not uniform. Do not replace diabetes prevention or treatment with HRT.

Does estrogen improve blood sugar control?▼

Estrogen-based therapy has shown modest improvements in fasting glucose and insulin sensitivity in some trials of early postmenopausal women. Effects are most consistent with transdermal routes and are not strong enough to treat diabetes.

HRT and metabolic syndrome▼

Menopause accelerates central fat accumulation and metabolic dysfunction. HRT may partially blunt these changes, but it is not indicated as metabolic syndrome treatment.

progesterone vs progestin insulin resistance▼

Synthetic progestins may attenuate estrogen's favorable metabolic effects more than micronized progesterone. Route and regimen selection can matter for metabolic outcomes.

Estrogen insulin sensitivity▼

Some studies show improved insulin sensitivity with estrogen-based therapy in early postmenopause, but results are not uniform across regimens. HRT should not replace evidence-based diabetes prevention or treatment.

HRT metabolic effects▼

Some studies show improved insulin sensitivity with estrogen-based therapy in early postmenopause, but results are not uniform across regimens. HRT should not replace evidence-based diabetes prevention or treatment.

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 6 relevant studies.

Overall finding

3 studies address ldl-c, with weighted findings showing mixed findings. 2 studies address major adverse cardiovascular events, with weighted findings showing mixed findings. 1 study addresses hba1c / glycemic control, with weighted findings showing unclear findings. 1 study addresses weight / body composition, with weighted findings showing unclear findings. 6 randomized or systematic-review reports and 0 observational studies address treatment.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Mixed

LDL-C

moderate · 3 studies

3 studies address ldl-c, with weighted findings showing mixed findings. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 31447131PMID 22607822PMID 18997196
Mixed

Major adverse cardiovascular events

moderate · 2 studies

2 studies address major adverse cardiovascular events, with weighted findings showing mixed findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 30146931PMID 18997196
Unclear

HbA1c / glycemic control

moderate · 1 study

1 study addresses hba1c / glycemic control, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 10100178
Unclear

Weight / body composition

moderate · 1 study

1 study addresses weight / body composition, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 10100178
Negative link

Mortality

moderate · 1 study

1 study addresses mortality, with weighted findings showing a negative association. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 22607822

Magnitude / clinical importance

Validated effect estimates in the analyzed set include RR 0. Statistical significance is not the same as clinical importance.

Where quantified, effects were often statistically detectable but small in absolute terms.

Agreement across studies

High-influence studies disagree on direction. Weighted interpretation, not vote counting, determines the synthesis.

Supports main conclusion: 5 · Neutral / mixed: 1 · Credible conflicting: 0

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

  • The Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial of patients at high risk of vascular disease found that adding extended-release niacin-lar…
  • Statins reduce LDL cholesterol and prevent vascular events, but their net effects in people at low risk of vascular events remain uncertain.
  • Aspirin use prevented serious vascular events in persons who had diabetes and no evident cardiovascular disease at trial entry, but it also caused major bleeding events.
  • In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascul…

Risks & harms

2 studies report safety-relevant findings. Design mix: Randomized controlled trial. Rare-event inference should not rest on underpowered trials alone.

Who this applies to

Most studies included postmenopausal women.

What remains uncertain

  • Metabolic effects differ by estrogen type, route, and menopause stage; trials are heterogeneous and not powered for hard outcomes.
  • Metabolic effects differ by estrogen type, route, and menopause stage; trials are heterogeneous and not powered for hard outcomes.

Clinical takeaway

Consider early postmenopausal estrogen when vasomotor symptoms and metabolic risk coexist, without substituting HRT for diabetes prevention or treatment. Monitor glucose and weight regardless of hormone regimen.

Mixed

LDL-C?

Mixed findings

moderate[31447131 · 22607822 · 18997196]

Mixed

Major adverse cardiovascular events?

Mixed findings

moderate[30146931 · 18997196]

Unclear

HbA1c / glycemic control?

Unclear findings

moderate[10100178]

Unclear

Weight / body composition?

Unclear findings

moderate[10100178]

Negative link

Mortality?

A negative association

moderate[22607822]

6 randomized or systematic-review reports and 0 observational studies address treatment. Weighted treatment findings show mixed findings.

6 RCT / systematic review · 0 observational

Large randomized trials strongly influence the conclusion

2 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

12 supporting studies add context beyond the core evidence base.

Regimen & duration

Differences in hormone type, dose, duration, and patient population affect how results should be interpreted.

Long-term uncertainty

Study quality or consistency across available evidence limits certainty.

6 analyzed studies

Strongest evidence

Supporting literature

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.

Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.

+9 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Cardiometabolic Risk.

Is ApoB more useful than LDL-C for cardiovascular risk prediction?

Prospective cohorts and meta-analyses suggest ApoB may capture atherogenic particle burden better than LDL-C alone, particularly when triglycerides are elevated or LDL particles are discordant with LDL-C.

14 linked studies

Should adults take statins for primary cardiovascular prevention?

Meta-analyses of primary prevention trials show reduced major adverse cardiovascular events with statins in appropriately selected moderate-to-high-risk adults. Shared decision-making should weigh absolute risk reduction against side effects and patient preference.

12 linked studies

Does elevated lipoprotein(a) independently increase cardiovascular risk?

Mendelian randomization and epidemiologic data support Lp(a) as a causal cardiovascular risk factor. Specific Lp(a)-lowering therapies are emerging but routine treatment beyond standard risk factor control awaits outcome trial confirmation.

11 linked studies

Does hormone therapy improve metabolic syndrome markers?

Menopausal hormone therapy may favorably affect some metabolic markers in selected women but is not a primary treatment for metabolic syndrome. Lifestyle and cardiometabolic risk management remain foundational.

14 linked studies

Go deeper on Cardiometabolic Risk

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.

Ask RAGMDExplore Cardiometabolic RiskView pricing